Leerink Partners analyst Jonathan Chang has maintained their bullish stance on IMTX stock, giving a Buy rating on November 6. Jonathan ...
Immatics (IMTX) has released an update. Immatics is showcasing promising advancements in its TCR-T therapy candidates targeting PRAME, with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback